Experimental vaccines tested to train immune system against HPV cancers
NCT ID NCT04180215
Summary
This study tested two experimental vaccines called HB-201 and HB-202 designed to teach the body's immune system to recognize and attack HPV 16-positive cancer cells. The trial involved 198 patients with advanced head and neck cancers caused by HPV 16, who received the vaccines alongside standard immunotherapy (pembrolizumab). Researchers aimed to find safe doses and see if the combination could shrink tumors in patients who were either newly diagnosed or had previously received treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, Locatie VUMC
Amsterdam, 1081, Netherlands
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Centro Integral Oncologico Clara Campal
Madrid, 28050, Spain
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Greenville Hospital System University Medical Center (ITOR)
Greenville, South Carolina, 29605, United States
-
Grossman School of Medicine
New York, New York, 10016, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario Virgen Macarena
Seville, 410009, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 8041, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Loyola University Medical School
Maywood, Illinois, 60153, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Montefiore-Einstein Center for Cancer Care
The Bronx, New York, 10461, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
O'Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama, 35294, United States
-
Perlmutter Cancer Center at NYU Langone Hospital-Long Island
New York, New York, 11501, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCLA (University of California, Los Angeles)
Los Angeles, California, 90095, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Arkansas for Medical Sciences, Cancer Institute, Clinical Trials Office
Fayetteville, Arkansas, 72205, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
-
University of Kansas Medical Center
Fairway, Kansas, 66205, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virgina Health System
Charlottesville, Virginia, 22908, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.